New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
Disease control
Recruiting now
This early-phase trial is testing a new cell therapy called GF-CART01 for people with certain B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two cancer markers (CD…
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC